TY - JOUR
T1 - Factors associated with serum ferritin levels and iron excess
T2 - results from the EPIC-EurGast study
AU - Iglesias-Vázquez, Lucía
AU - Arija, Victoria
AU - Aranda, Núria
AU - Aglago, Elom K.
AU - Cross, Amanda J.
AU - Schulze, Matthias B.
AU - Quintana Pacheco, Daniel
AU - Kühn, Tilman
AU - Weiderpass, Elisabete
AU - Tumino, Rosario
AU - Redondo-Sánchez, Daniel
AU - de Magistris, Maria Santucci
AU - Palli, Domenico
AU - Ardanaz, Eva
AU - Laouali, Nasser
AU - Sonestedt, Emily
AU - Drake, Isabel
AU - Rizzolo, Lucía
AU - Santiuste, Carmen
AU - Sacerdote, Carlotta
AU - Quirós, Ramón
AU - Amiano, Pilar
AU - Agudo, Antonio
AU - Jakszyn, Paula
N1 - Funding Information:
We thank the European Commission (DG-SANCO) and the International Agency for Research on Cancer for the financial support to the coordination of EPIC study. The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), the National Institute for Public Health and the Environment–Bilthoven (RIVM), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the catal Institute of Oncology (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK). We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Funding Information:
We thank the European Commission (DG-SANCO) and the International Agency for Research on Cancer for the financial support to the coordination of EPIC study. The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), the National Institute for Public Health and the Environment–Bilthoven (RIVM), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the catal Institute of Oncology (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK). We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Funding Information:
This study has been funded by Instituto de Salud Carlos III (project ref. PI11/1486), by European Regional Development Fund through the project “A way to build Europe”, and by the World Cancer Research Fund (Grant ref. 2011/428).
Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: Excess iron is involved in the development of non-communicable diseases such as cancer, type 2 diabetes and cardiovascular conditions. We aimed to describe the prevalence of excess iron and its determinants in healthy European adults. Methods: Sociodemographic, lifestyle, iron status, dietary information, and HFE genotyping were obtained from controls from the nested case–control study EPIC-EurGast study. High sensitivity C-reactive protein (hsCRP) was measured to address possible systemic inflammation. Descriptive and multivariate analyses were used to assess iron status and its determinants. Results: Out of the 828 participants (median age: 58.7 years), 43% were females. Median serum ferritin and prevalence of excess iron were 143.7 µg/L and 35.2% in males, respectively, and 77 µg/L and 20% in females, both increasing with latitude across Europe. Prevalence of HFE C282Y mutation was significantly higher in Northern and Central Europe (~ 11%) than in the South (5%). Overweight/obesity, age, and daily alcohol and heme iron intake were independent determinants for iron status, with sex differences even after excluding participants with hsCRP > 5 mg/L. Obese males showed a greater consumption of alcohol, total and red meat, and heme iron, compared with those normal weight. Conclusion: Obesity, higher alcohol and heme iron consumption were the main risk factors for excess iron in males while only age was associated with iron overload in females. Weight control and promoting healthy lifestyle may help prevent iron overload, especially in obese people. Further research is needed to clarify determinants of excess iron in the healthy adult population, helping to reduce the associated comorbidities.
AB - Purpose: Excess iron is involved in the development of non-communicable diseases such as cancer, type 2 diabetes and cardiovascular conditions. We aimed to describe the prevalence of excess iron and its determinants in healthy European adults. Methods: Sociodemographic, lifestyle, iron status, dietary information, and HFE genotyping were obtained from controls from the nested case–control study EPIC-EurGast study. High sensitivity C-reactive protein (hsCRP) was measured to address possible systemic inflammation. Descriptive and multivariate analyses were used to assess iron status and its determinants. Results: Out of the 828 participants (median age: 58.7 years), 43% were females. Median serum ferritin and prevalence of excess iron were 143.7 µg/L and 35.2% in males, respectively, and 77 µg/L and 20% in females, both increasing with latitude across Europe. Prevalence of HFE C282Y mutation was significantly higher in Northern and Central Europe (~ 11%) than in the South (5%). Overweight/obesity, age, and daily alcohol and heme iron intake were independent determinants for iron status, with sex differences even after excluding participants with hsCRP > 5 mg/L. Obese males showed a greater consumption of alcohol, total and red meat, and heme iron, compared with those normal weight. Conclusion: Obesity, higher alcohol and heme iron consumption were the main risk factors for excess iron in males while only age was associated with iron overload in females. Weight control and promoting healthy lifestyle may help prevent iron overload, especially in obese people. Further research is needed to clarify determinants of excess iron in the healthy adult population, helping to reduce the associated comorbidities.
KW - EPIC
KW - Excess iron
KW - Iron overload
KW - Iron status
KW - Serum ferritin
UR - http://www.scopus.com/inward/record.url?scp=85109343680&partnerID=8YFLogxK
U2 - 10.1007/s00394-021-02625-w
DO - 10.1007/s00394-021-02625-w
M3 - Article
C2 - 34213605
AN - SCOPUS:85109343680
SN - 1436-6207
VL - 61
SP - 101
EP - 114
JO - European Journal of Nutrition
JF - European Journal of Nutrition
IS - 1
ER -